Surrey, BC, August 12, 2022--Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and the James Hutton Institute (JHI).
Surrey, BC, January 19, 2022--Eyam Vaccines and Immunotherapeutics has publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the company's Board of Directors, and the appointment of Dr. Nathan Lack and Dr. Marc Horwitz to its Scientific Advisory Board.
Vancouver, BC, April 16, 2021--Vancouver-based Eyam Vaccines and Immunotherapeutics (EYAM) has announced the commencement of preclinical studies to test the efficacy of unique COVID-19 vaccine candidates that target SARS-CoV-2 variants.